VRTX
Vertex Pharmaceuticals · Health Care
4.4%
typical move (median |reaction| of last 8)
2026-11-02 post · likely
next expected · estimated from pattern
12
scored events
Last eight reactions
2024-11-04 → 2026-08-03
| date | session | reaction | |move| | excess 5s | excess 20s |
|---|---|---|---|---|---|
| 2026-08-03 | post | +1.8% | 1.8% | +10.7% | +15.6% |
| 2026-05-04 | post | -1.3% | 1.3% | +3.7% | -3.2% |
| 2026-02-12 | post | +5.9% | 5.9% | -2.3% | -3.3% |
| 2025-11-03 | post | -1.1% | 1.1% | +0.7% | +8.7% |
| 2025-08-04 | post | -20.5% | 20.5% | +1.2% | +3.3% |
| 2025-05-05 | post | -9.4% | 9.4% | -9.7% | -8.1% |
| 2025-02-10 | post | -3.1% | 3.1% | +2.4% | +16.4% |
| 2024-11-04 | post | +5.6% | 5.6% | -5.5% | -12.6% |
Source filings
2026-08-03 · 8-K press release
Vertex Reports Second Quarter 2026 Financial Results — Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 b
2026-05-04 · 8-K press release
Vertex Reports First Quarter 2026 Financial Results — Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 — — Povetacicept program continues rapid advancement: Completed roll
2026-02-12 · 8-K press release
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results — Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion,
2025-11-03 · 8-K press release
Vertex Reports Third Quarter 2025 Financial Results — Total revenue of $3.08 billion, an 11% increase compared to Q3 2024 — — Refined full year financial guidance: total revenue guidance now $11.9 to
2025-08-04 · 8-K press release
Vertex Reports Second Quarter 2025 Financial Results — Total revenue of $2.96 billion, a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $
2025-05-05 · 8-K press release
Vertex Reports First Quarter 2025 Financial Results — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of
2025-02-10 · 8-K press release
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results — Full year product revenue of $11.02 billion, a 12% increase compared to full year 2023 — — Company provides full year 2025 total re
2024-11-04 · 8-K press release
Vertex Reports Third Quarter 2024 Financial Results — Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 bill